Povorcitinib clinical trials
Also written INCB054707.
Includes 1 study of Povorcitinib phosphate.
How each study uses povorcitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the povorcitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 0
Incyte Corporation (22) · Incyte Biosciences Japan GK (1) · Dermavon Holdings Limited (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Levonorgestrel (1) · Ethinyl Estradiol (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test povorcitinib, phase 3 first.
- Dec 2026A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaPhase 3 · Incyte Corporation
- Nov 2026A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaPhase 2 · Incyte Corporation
Studies
Open first, then newest update. How each study uses povorcitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibRecruitingPhase 3Incyte CorporationNCT06855498Written as povorcitinib
- Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingPhase 2Incyte CorporationNCT07213973Written as Povorcitinib
- A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental VitiligoNot yet recruitingPhase 3Dermavon Holdings LimitedNCT07865312Written as Povorcitinib phosphate
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Active, not recruitingPhase 3Incyte CorporationNCT06516965Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedPhase 3Incyte CorporationNCT05620836Written as Povorcitinib
- A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsCompletedPhase 1Incyte CorporationNCT07588139Written as Povorcitinib
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingPhase 3Incyte CorporationNCT06212999Written as Povorcitinib
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Active, not recruitingPhase 3Incyte CorporationNCT06113445Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaActive, not recruitingPhase 2Incyte CorporationNCT05851443Written as povorcitinib
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Active, not recruitingPhase 3Incyte CorporationNCT06516952Written as Povorcitinib
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Active, not recruitingPhase 3Incyte CorporationNCT06113471Written as Povorcitinib
- Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaCompletedPhase 2Incyte CorporationNCT05936567Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3Incyte CorporationNCT05620823Written as Povorcitinib
- A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedPhase 2Incyte CorporationNCT03607487Written as INCB054707
- To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedPhase 2Incyte CorporationNCT04476043Written as INCB054707
- A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedPhase 1Incyte CorporationNCT05624710Written as INCB054707
- A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo NodularisCompletedPhase 2Incyte CorporationNCT05061693Written as INCB054707
- A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy ParticipantsCompletedPhase 1Incyte CorporationNCT06505265Written as Povorcitinib
- A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy ParticipantsCompletedPhase 1Incyte CorporationNCT06441318Written as Povorcitinib
- A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesCompletedPhase 1Incyte CorporationNCT06380205Written as Povorcitinib
See all 24 studies that test povorcitinib →
Given beside what is tested · 1 — povorcitinib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call povorcitinib · ClinicalTrials.gg INT017344
- UNII (FDA) N0JWC7RO00POVORCITINIBOne source FDA
- NCI Thesaurus C188603PovorcitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N0JWC7RO00 | POVORCITINIB | One source FDA |
| NCI Thesaurus | C188603 | Povorcitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.